OmniSpirant Limited has received funding from the European Union’s Horizon 2020 research and innovation programme under SME Instrument grant agreement 855463_ReSpire

The Celtic Advanced Life Science Innovation Network (CALIN) is a 4-year Ireland-Wales INTERREG operation funded by the European Regional Development Fund through the Welsh Government.

Registered Address

Clonmel, Co. Tipperary, Ireland

Contact

©2019 OMNISPIRANT LIMITED

 

Game Changing Innovation in Respiratory Medicine 

At OmniSpirant, we believe our technology has the potential to positively impact the lives of millions of patients. We have created a bold new approach to treat currently incurable respiratory diseases that affect hundreds of millions of people worldwide. Our planned pipeline of advanced therapies intersect regenerative medicine and gene therapy in the hope of treating these devastating lung diseases of severely unmet patient need. Our patent pending platform technology is based on inhaled bioengineered stem cell exosomes which are capable of  efficient intracellular delivery of a variety of therapeutic cargoes to effectively treat these diseases at the required level of complexity. Our engineered stem cell exosomes will initially be used to develop a first in class regenerative gene therapy for Cystic Fibrosis. The prorietatry mucus penetrating exosomes have similar transformative potential for treating many other respiratory diseases.  Please browse our site to learn more about our mission and technology.

 

INHALED EXOSOME TECHNOLOGY PLATFORM

Exosomes genetic cargo can be tailored to treat virtually any lung disease

Exosomes exhibit unparalleled intracellular delivery and therapeutic properties

CONTACT US